
References: Why use Hyperthermia to treat NMIBC?

- a. Dahl, O., Dalene, R., Schem, B. C. & Mella, O. Status of clinical hyperthermia. *Acta Oncol.* 38, 863–73 (1999).
 - b. Song, C. W. Effect of Local Hyperthermia on Blood Flow and Microenvironment: A Review. *Cancer Res.* 44, 4721s – 4730s (1984).
 - c. Teicher, B. A., Kowal, C. D., Kennedy, K. A. & Sartorelli, A. C. Enhancement by Hyperthermia of the in Vitro Cytotoxicity of Mitomycin C toward Hypoxic Tumor Cells. *Cancer Res.* 41, 1096–1099 (1981).
 - d. Fajardo, L., Prionas, S., Kowalski, J. & Kwan, H. Hyperthermia inhibits angiogenesis. *Radiat Res* 114, 297–306 (1988).
 - e. Fuse, T., Yoon, K., Kato, T. & Yamada, K. Heat-induced apoptosis in human glioblastoma cell line A172. *Neurosurgery* 42, 843–9 (1998).
 - f. Adapted from Company Data Kyowa <http://www.mitomycin.net/professionals/about03.html>
 - g. Paroni, R. et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. *Br. J. Clin. Pharmacol.* 52, 273–8 (2001).
 - h. Crooke, S. T., Henderson, M., Samson, M. & Baker, L. H. Phase I study of oral mitomycin C. *Cancer Treat. Rep.* 60, 1633–6 (1976).
-